4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 5.2% – What’s Next?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price shot up 5.2% on Tuesday . The company traded as high as $10.78 and last traded at $10.9650. 101,193 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 767,988 shares. The stock had previously closed at $10.42.

Analyst Ratings Changes

Several research analysts have recently issued reports on FDMT shares. Chardan Capital restated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Royal Bank Of Canada boosted their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Finally, Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Price Performance

The firm has a market cap of $573.30 million, a P/E ratio of -4.26 and a beta of 2.75. The stock’s 50 day moving average is $9.44 and its two-hundred day moving average is $9.12.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. As a group, research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently modified their holdings of FDMT. Sei Investments Co. boosted its stake in 4D Molecular Therapeutics by 8.9% in the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after buying an additional 1,050 shares in the last quarter. Martingale Asset Management L P raised its stake in 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after acquiring an additional 1,303 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in 4D Molecular Therapeutics by 3.7% during the third quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock worth $504,000 after acquiring an additional 2,069 shares in the last quarter. Russell Investments Group Ltd. raised its stake in 4D Molecular Therapeutics by 11.7% during the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after acquiring an additional 2,284 shares in the last quarter. Finally, Prelude Capital Management LLC lifted its holdings in shares of 4D Molecular Therapeutics by 11.1% during the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock valued at $200,000 after acquiring an additional 2,300 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.